

State of the art in the treatment of hematological malignancies

IV Pre Congress Meeting SEHH 2015

Chairman:

Dr. Miguel Ángel Sanz

Hospital Universitari i Politènic La Fe. Valencia

Valencia,

21st October 2015

Palacio de Congresos de Valencia

Venue

Palacio de Congresos de Valencia

Avda. Cortes Valencianas, nº 60. Valencia

Organized by



Under the auspices of:



Thanks to an unrestricted grant of 

MULTIPLE MYELOMA (MM) SESSION

Chair: Dr. Jesús F. San Miguel. Clínica Universidad de Navarra. Pamplona

Clinical decisions based on MM biology

- 11:00-11:15 h **The extent of intra-clonal genetic diversity within the myeloma clone**
Dr. Gareth Morgan. Myeloma Institute For Research and Therapy, University of Arkansas For Medical Sciences, Arkansas (USA)
- 11:15-11:30 h **Contributions of flow cytometry to biological knowledge and clinical behavior of MM. Optimizing MRD technique**
Dr. Bruno Paiva. CIMA Lab Diagnostics, Universidad de Navarra-Clinica Universidad de Navarra, Pamplona
- 11:30-11:45 h **When I have to treat? SMM, biological relapse vs. CRAB**
Dr. Joan Bladé. Hospital Clinic, Barcelona
- 11:45-11:55 h **Panel discussion**

Current management and challenges in MM treatment

- 11:55-12:10 h **Optimizing the treatment of patients no SCT candidates and measuring quality of life and its contribution to the value of novel agents**
Dr. M.ª Victoria Mateos. Hospital Universitario de Salamanca
- 12:10-12:25 h **Optimizing the treatment of patients SCT candidates in the era of the novel agents**
Dr. Juan José Lahuerta. Hospital Universitario 12 de Octubre, Madrid
- 12:25-12:40 h **Second and third generation of PI & IMiDs for relapsed and refractory patients**
Dr. Enrique M. Ocio. Hospital Universitario de Salamanca
- 12:40-12:55 h **Immune checkpoint inhibitors in MM and other hematological malignancies**
Dr. Paula Rodríguez. Clínica Universidad de Navarra, Pamplona
- 12:55-13:05 h **Panel discussion**
- 13:05 h **Lunch**

NON-HODKING LYMPHOMA (NHL) SESSION

Chair: Dr. M.ª Dolores Caballero. Hospital Universitario de Salamanca

Diffuse large B-cell lymphoma (DLBCL). Expert panel

- 14:45-15:00 h **Lessons to be learned from molecular analysis**
Dr. Santiago Montes-Moreno. Hospital Universitario Marqués de Valdecilla, Santander
- 15:00-15:15 h **Improving R-CHOP treatment**
Dr. Annalisa Chiappella. Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino (Italy)
- 15:15-15:25 h **Panel discussion**

NON-HODKING LYMPHOMA (NHL) SESSION (continue)

Follicular lymphoma (FL). Expert panel

- 15:25-15:40 h **Front-line therapy in advanced stage**
Dr. Franck Morschhauser. Centre Hospitalier Régional Universitaire de Lille, Lille (France)
- 15:40-15:55 h **Relapsed/refractory status: old/new agents**
Dr. Armando López Guillermo. Hospital Clinic, Barcelona
- 15:55-16:05 h **Panel discussion**
- Mantle cell lymphoma (MCL). Expert panel**
- 16:05-16:20 h **Optimizing strategies of ASCT in MCL**
Dr. Alejandro Martín. Hospital Universitario de Salamanca
- 16:20-16:35 h **New drugs in MCL**
Dr. Steven Le Gouill. Centre Hospitalier Universitaire de Nantes, France
- 16:35-16:45 h **Panel discussion**
- 16:45 h **Coffee break**

MYELODYSPLASIA (MDS) SESSION

Chair: Dr. Guillermo Sanz. Hospital Universitari i Politècnic La Fe, Valencia

- 17:15-17:30 h **Citogenetic abnormalities**
Dr. Juan Cruz Cigudosa. Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid
- 17:30-17:45 h **Insight in the future treatment options for MDS patients**
Dr. Valeria Santini. University of Florence Medical School, Florence (Italy)
- 17:45-18:00 h **Targeted treatment and cytogenetic abnormalities in MDS**
Dr. David Valcárcel. Hospital Universitari Vall d'Hebron, Barcelona
- 18:00-18:10 h **Panel discussion**

ACUTE MYELOID LEUKEMIA (AML) SESSION

Chair: Dr. Miguel Ángel Sanz. Hospital Universitari i Politècnic La Fe, Valencia

- 18:10-18:25 h **Preclinical studies in AML**
Dr. José Antonio Pérez Simón. Hospital Universitario Virgen del Rocío, Sevilla
- 18:25-18:40 h **Optimizing the management of AML patients (European perspective)**
Dr. Lisa Pleyer. Salzburg Cancer Research Institute-Center For Clinical Cancer and Immunology Trials, Salzburg (Austria)
- 18:40-18:55 h **Optimizing the management of AML patients (Spanish perspective)**
Dr. Pau Montesinos. Hospital Universitari i Politècnic La Fe, Valencia
- 18:55-19:05 h **Panel discussion**